Search Results
147 results found-
IFK Gesamtzahl der Empfänger geldwerter Leistungen pro Unterart 5 17 - - - - 22 Prozentualer Anteil im Verhältnis zu allen IFK-Empfängern geldwerter Leistungen pro Unterart 100% 52% 0% 0% 0% 0% N/A
https://www.csl.com/-/media/shared/documents/vifor-disclosures/disclosure-reports/disclosure-report-austria-2020-v1.pdf -
Die durch uns verarbeiteten personenbezogenen Daten Pharma ausgewählt werden, werden Ihre können die folgenden Arten sensibler personen- personenbezogenen Daten darüber hinaus dazu genutzt, bezogener Informationen umfassen:
https://www.csl.com/-/media/shared/documents/vifor-disclosures/recruiting/privacy-notice-for-recruiting-german.pdf -
Seqirus operates state-of-the-art production facilities in Research and Development the US, the United Kingdom (UK) and Australia, Manufacturing and utilises both egg-based and cell-based manufacturing technologies as well as a Commercial Operations proprietary adjuvant.
https://www.csl.com/-/media/csl/documents/csl-statement-on-modern-slavery-2021.pdf -
Die Art und Weise, wie CSL diesen Verpflichtungen nachkommt, wird ausführlich in dem auf CSL.com verfügbaren CSL-Kodex für verantwortliche Geschäftspraktiken beschrieben.
https://www.csl.com/-/media/shared/documents/one-csl/csl-third-party-code-of-conduct-2021/csl-third-party-code-of-conduct_2021_german.pdf -
Ich lade Sie ein, den Kodex zu lesen und zu verstehen, wie er sich auf Ihre Funktion und die Art auswirkt, in der Sie CSL im Geschäft und in der weiteren Gemeinschaft repräsentieren.
https://www.csl.com/-/media/shared/documents/one-csl/crbp-languages/csl_crbp2021_german_external.pdf -
City of Unique country Country of Principal Donations and Fee for service and consultancy (Art.
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/disclosures-2019/seqirus_template_2019_abpi_internal.pdf -
spesifisering er tilgjengelig bare på forespørsel fra den enkelte mottager eller vedkommende offentlige myndigheter) Norsk Diabetikersenter For Behandling Og Oslo Norge Sponhoggveien 19 16'000.00 16'000.00 Opplæring Norsk gastroenterologisk forening Oslo Norge Akersgata 2 12'000.00 12'000.00 NSFs -Landsgruppe av kardiologiske Kristiansand Norge Møllevannsveien 77C 8'000.00 8'000.00 sykepleiere Sadollah Abedini enkeltmannsforetak Tønsberg Norge Hyttebakken 5 27'295.64 27'295.64 Thomas von Lueder Cardioconsult Oslo Norge Arbins Gate 9A 10'000.00 10'000.00 Vestnorsk cardiologisk forening Bergen Norge Jonas Lies vei 65 c/o Haukeland 12'000.00 12'000.00 ANNET, IKKE INKLUDERT OVER -hvis informasjon ikke kan offentliggjøres individuelt av juridiske hensyn Helseorganisasjoner Samlet beløp som kan tilskrives verdioverføringer til slike mottagere - Art.
https://www.csl.com/-/media/shared/documents/vifor-disclosures/disclosure-reports/disclosure-report-norway-2020.pdf -
Seqirus operates state-of-the-art production facilities in the US, the United Kingdom (UK) and Australia, and utilises both egg-based and cell-based Research and Development manufacturing technologies as well as a Manufacturing proprietary adjuvant.
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/disclosures-2020/csl-statement-on-modern-slavery-2020.pdf -
EUR Corrispettivi per prestazioni Contributi per il finanziamento di Eventi (Art.
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/disclosures-2019/seqirus-italy-2019.pdf -
US$3.7 27,000+ Seqirus operates state-of-the-art production facilities in the Billion in R&D investments Employees around United States (US), the United Kingdom (UK) and Australia in the last 5 years advances the world and utilises both egg-based and cell-based manufacturing product pipeline technologies as well as a proprietary adjuvant.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf